Phase 1/2Terminated
A Study of VLX1570 and Dexamethasone in Myeloma Patients
VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study
- Sponsor
- Vivolux AB (Industry)
- Enrolment
- 15 enrolled
- Conditions
- Multiple Myeloma
- Interventions
- VLX1570 and dexamethasone
- Ages
- adults, older adults
- Registry
- NCT02372240
Full record on ClinicalTrials.gov
From the registry
This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
Primary outcomes
- Maximum tolerated dose (MTD) of VLX1570 with low dose dexamethasone
- Clinical benefit rate (minimal response or better) in patients associated with administration of VLX1570 with low dose dexamethasone
History
Last registry update
Primary completion
Started
Registered